rofecoxib has been researched along with Thrombosis in 31 studies
Thrombosis: Formation and development of a thrombus or blood clot in the blood vessel.
Excerpt | Relevance | Reference |
---|---|---|
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 7.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 7.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
"We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 7.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
"Main parameter was thrombus weight." | 5.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
"Using an intention-to-treat analysis of adjudicated CVT deaths, we analyzed detailed patient-level data collected during 3 randomized placebo-controlled trials of rofecoxib versus placebo that had been designed to define the drug's possible role in the prevention or treatment of Alzheimer disease." | 3.78 | Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. ( Avorn, J; Furberg, CD; Madigan, D; Mayer, JW; Sigelman, DW, 2012) |
"It was predicted from the mechanism of action that, compared to older non-steroidal anti-inflammatory drugs, rofecoxib (Vioxx) would reduce gastrointestinal bleeding, but also that it would increase the occurrence of cardiovascular thrombosis." | 3.76 | Unbalanced reporting of benefits and harms in abstracts on rofecoxib. ( Gøtzsche, PC; Jørgensen, AW; Jørgensen, KJ, 2010) |
"The potential prothrombotic effect of the cyclooxygenase-2 (COX-2) inhibitor Rofecoxib (Vioxx) was investigated using murine thrombosis models." | 3.74 | Prothrombotic effect of Rofecoxib in a murine venous thrombosis model. ( Gallacher, DJ; Hoylaerts, MF; Lijnen, HR; Lu, HR; Nagai, N, 2008) |
"We conclude that under our experimental conditions, rofecoxib diminished platelet aggregation induced by different agonists and inhibited platelet-mediated thrombogenesis in an in vitro model of thrombosis." | 3.72 | Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood. ( Arderiu, G; Escolar, G; Hernandez, MR; Pino, M; Serradell, M; Tonda, R, 2004) |
" To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
" In the VIGOR gastrointestinal outcomes trial of >8000 patients, naproxen (an NSAID with aspirin-like sustained antiplatelet effects throughout its dosing interval) was associated with a significantly lower risk of CV events than was rofecoxib." | 2.42 | Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. ( Gertz, BJ; Reicin, A; Sperling, RS; Weir, MR, 2003) |
" Comparisons were made between patients taking rofecoxib and those taking either placebo, naproxen (an NSAID with near-complete inhibition of platelet function throughout its dosing interval), or another nonselective NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone)." | 2.41 | Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. ( Barr, E; Gertz, BJ; Konstam, MA; Reicin, A; Shapiro, D; Sperling, RS; Weir, MR, 2001) |
"Rofecoxib was withdrawn from the market on 30 September 2004 following the results of a randomized controlled trial." | 1.35 | Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004? ( Bagheri, H; Grolleau, S; Lapeyre-Mestre, M; Montastruc, JL; Sommet, A, 2008) |
"Main parameter was thrombus weight." | 1.32 | Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 27 (87.10) | 29.6817 |
2010's | 4 (12.90) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sommet, A | 1 |
Grolleau, S | 1 |
Bagheri, H | 1 |
Lapeyre-Mestre, M | 1 |
Montastruc, JL | 1 |
Nagai, N | 1 |
Hoylaerts, MF | 1 |
Gallacher, DJ | 1 |
Lu, HR | 1 |
Lijnen, HR | 1 |
Baigent, C | 1 |
Patrono, C | 1 |
Jørgensen, AW | 1 |
Jørgensen, KJ | 1 |
Gøtzsche, PC | 1 |
Kaber, G | 1 |
Kaiser, B | 1 |
Baumgärtel-Allekotte, D | 1 |
Rauch, B | 1 |
Nossmann, S | 1 |
Heim, Kh | 1 |
Weber, A | 1 |
Nagy, N | 1 |
Fischer, J | 1 |
Schrör, K | 2 |
Khan, M | 1 |
Fraser, A | 1 |
Madigan, D | 1 |
Sigelman, DW | 1 |
Mayer, JW | 1 |
Furberg, CD | 1 |
Avorn, J | 1 |
Jaeschke, R | 1 |
Gajewski, P | 1 |
Brozek, J | 1 |
Bannwarth, B | 1 |
Ravaud, P | 1 |
Dougados, M | 1 |
Girardin, F | 1 |
Siegenthaler, M | 1 |
De Moerloose, P | 1 |
Desmeules, J | 1 |
Konstam, MA | 3 |
Weir, MR | 2 |
Sperling, RS | 3 |
Reicin, A | 2 |
Gertz, BJ | 2 |
Hernandez, MR | 1 |
Tonda, R | 1 |
Pino, M | 1 |
Serradell, M | 1 |
Arderiu, G | 1 |
Escolar, G | 1 |
Umar, A | 1 |
Boisseau, M | 1 |
Yusup, A | 1 |
Upur, H | 1 |
Bégaud, B | 1 |
Moore, N | 1 |
Couzin, J | 1 |
Bresalier, RS | 1 |
Sandler, RS | 1 |
Quan, H | 1 |
Bolognese, JA | 1 |
Oxenius, B | 1 |
Horgan, K | 1 |
Lines, C | 1 |
Riddell, R | 1 |
Morton, D | 1 |
Lanas, A | 1 |
Baron, JA | 1 |
Alpert, JS | 1 |
Fries, S | 1 |
Grosser, T | 1 |
Price, TS | 1 |
Lawson, JA | 1 |
Kapoor, S | 1 |
DeMarco, S | 1 |
Pletcher, MT | 1 |
Wiltshire, T | 1 |
FitzGerald, GA | 2 |
Rashid, A | 1 |
Dale, G | 1 |
Hennebry, T | 1 |
Lagakos, SW | 1 |
Steffel, J | 1 |
Akhmedov, A | 1 |
Fähndrich, C | 1 |
Ruschitzka, F | 1 |
Lüscher, TF | 1 |
Tanner, FC | 1 |
Mukherjee, D | 2 |
Sibilia, J | 1 |
Deray, G | 2 |
Montalescot, G | 1 |
Valat, JP | 1 |
Héloire, F | 1 |
Weber, AA | 1 |
Heim, HK | 1 |
Schumacher, M | 1 |
Hohlfeld, T | 1 |
Martínez-González, J | 1 |
Badimon, L | 1 |
Austin, S | 1 |
Egan, K | 1 |
Cheng, Y | 1 |
Pratico, D | 1 |
Shapiro, D | 2 |
Barr, E | 2 |
Reicin, AS | 1 |
Yu, Q | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of [NCT00282386] | Phase 3 | 2,586 participants (Actual) | Interventional | 1999-12-23 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
9 reviews available for rofecoxib and Thrombosis
Article | Year |
---|---|
Cox-2 inhibitors and the risk of cardiovascular thrombotic events.
Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Sulfones; Thrombosis | 2012 |
Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Blood | 2003 |
Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
Topics: Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Celecoxib; Cyclooxygenase 2 | 2006 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celeco | 2006 |
[Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseas | 2006 |
Mechanisms underlying the cardiovascular effects of COX-inhibition: benefits and risks.
Topics: Atherosclerosis; Cardiovascular Diseases; Consumer Product Safety; Cyclooxygenase 2; Cyclooxygenase | 2007 |
Cyclo-oxygenase products and atherothrombosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Epoprostenol; Humans; L | 2000 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascu | 2001 |
Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events.
Topics: Animals; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cycloox | 2002 |
4 trials available for rofecoxib and Thrombosis
Article | Year |
---|---|
Cardiovascular thrombotic events and COX-2 inhibitors: results in patients with osteoarthritis receiving rofecoxib.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Female; Humans; Isoe | 2003 |
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Topics: Adenomatous Polyps; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin | 2005 |
Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2.
Topics: Adult; Aryl Hydrocarbon Hydroxylases; Atherosclerosis; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors | 2006 |
Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers.
Topics: Adenosine Diphosphate; Adult; Aspirin; Atherosclerosis; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxy | 2007 |
18 other studies available for rofecoxib and Thrombosis
Article | Year |
---|---|
Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?
Topics: Adverse Drug Reaction Reporting Systems; Celecoxib; Cyclooxygenase 2 Inhibitors; Databases, Factual; | 2008 |
Prothrombotic effect of Rofecoxib in a murine venous thrombosis model.
Topics: Animals; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Femoral Artery; Jugular Veins; Lactone | 2008 |
Selective COX-2 inhibitors: where do we go from here?
Topics: Cyclooxygenase 2 Inhibitors; Humans; Lactones; Randomized Controlled Trials as Topic; Sulfones; Thro | 2008 |
Unbalanced reporting of benefits and harms in abstracts on rofecoxib.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; Gastrointest | 2010 |
Antagonism of the antithrombotic and anti-atherosclerotic actions of aspirin by rofecoxib in the cholesterol-fed rabbit.
Topics: Animal Feed; Animals; Aorta; Aspirin; Atherosclerosis; Cholesterol; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Cardiovascular Diseases; Cyclooxygenase | 2012 |
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
Topics: Aspirin; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Cyclooxygenase Inhibitors; Hu | 2002 |
Rofecoxib interaction with oral anticoagulant acenocoumarol.
Topics: Acenocoumarol; Administration, Oral; Adult; Anticoagulants; Antiphospholipid Syndrome; Biological Av | 2003 |
Matters of the heart: assessing the cardiovascular safety of new drugs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy | 2003 |
Evaluation of effects of rofecoxib on platelet function in an in vitro model of thrombosis with circulating human blood.
Topics: Adenosine Diphosphate; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Aspirin; Blood Pla | 2004 |
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy | 2004 |
Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors.
Topics: Blood Pressure; Clinical Trials as Topic; Colonic Polyps; Cyclooxygenase Inhibitors; Drug and Narcot | 2004 |
The Vioxx debacle.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Drug Approval; Humans; Lactones; | 2005 |
Cold leg in patient with high coated platelets: possible association with the use of rofecoxib.
Topics: Acute Disease; Blood Platelets; Coronary Artery Disease; Cyclooxygenase 2 Inhibitors; Eptifibatide; | 2006 |
Time-to-event analyses for long-term treatments--the APPROVe trial.
Topics: Adenomatous Polyps; Cyclooxygenase 2 Inhibitors; Data Interpretation, Statistical; Follow-Up Studies | 2006 |
Differential effect of celecoxib on tissue factor expression in human endothelial and vascular smooth muscle cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Celecoxib; Cell Line; Endothelium, Vascula | 2006 |
Cardiovascular safety of COX-2 inhibitors.
Topics: Cardiovascular Physiological Phenomena; Celecoxib; Consumer Product Safety; Cyclooxygenase Inhibitor | 2001 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |